Kayothera, Inc. Strengthens Financial Position With $5.2 Million In Grant And Expanded Series A Funding, Bringing Total Financial Support To $14 Million

Jul 19, 2023•over 2 years ago

Round Type

series a

PrincetonTherapeuticsBiotechnologyHealth Care

Investors

Kayo TheraWrf CapitalPier 70 VenturesBio AdvanceAlspAndy Hill Cancer Research Endowment Fund3National Institutes Of Health Small Business Innovation ResearchNew Jersey Health FoundationAccelerator Life Science Partners

Description

KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing first-in-class, oral, small molecule inhibitors of the retinoid pathway, today announces the strengthening of its financial resources through multiple grant awards and expansion of its previously announced Series A financing. The expanded financing was led by Accelerator Life Science Partners (ALSP), who also provided Series A funding for KayoThera. With the additional $5.2 million in new equity investments, non-dilutive grant funding, and initial seed funding from the New Jersey Health Foundation, KayoThera’s total financial support to date is $14 million.

Company Information

Company

KayoThera, Inc.

Location

155 VILLAGE BLVD., SUITE 130

Princeton, West Virginia, United States

About

KayoThera, Inc. is an early-stage therapeutics company focused on the development of first-in-class, oral, small molecule inhibitors of the retinoid pathway. This pathway plays a critical role in a variety of serious diseases, including cardiometabolic diseases and cancer. KayoThera is developing therapies to treat diabetes and late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and kidney cancers. The company was founded based on discoveries from Dr. Mark Esposito’s post-doctoral research at Princeton University and professor Yibin Kang, Ph.D. For more information, visit www.kayothera.com.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns